In a letter to the journal Science, top U.S. infectious disease experts join call for more information on the origins of the virus that causes COVID.
Author: Karen Weintraub, USA TODAY
CDC reports 13 additional cases of blood clots linked to J&J COVID-19 vaccine. All happened before 11-day pause in its use.
The newly revealed cases all occurred in people before the government’s 11-day pause in J&J’s single-dose vaccine last month.
Pfizer-BioNTech seeks full FDA approval for COVID-19 vaccine
Like other vaccines available in the U.S., Pfizer-BioNTech have been providing their vaccine under an emergency use authorization.
An experimental gene therapy was little Alissa’s only hope. Now, instead of certain death, she faces an uncertain future.
A scientific vision for decades, gene therapy is finally becoming more common in the U.S., fueling optimism for the treatment of rare diseases.
‘Like somebody gave me a happy pill:’ Monoclonal antibodies are helping the Americans most at risk for COVID-19
The therapy can be life-saving, especially in the early stages of an infection, and it’s becoming easier to access across the US.
A cautionary tale: COVID infection after vaccination is rare but breakthroughs can happen. It happened to this man.
The CDC says only 5,800 of the 75M Americans who have been fully vaccinated have contracted COVID-19. Carey Alexander Washington was one of them.
Scientists begin to unravel rare blood clotting disorder connected to J&J and AstraZeneca coronavirus vaccines
Although still murky, a picture is starting to emerge about the connection between two types of COVID-19 vaccines and rare blood clots.
‘We’re skating on a knife’s edge right now’: Scientists worry US could be headed for yet another COVID-19 surge
Scientists worry that rising COVID-19 case numbers might be the beginning of a fourth surge, though they don’t expect it to be as bad as others.
Should US share its COVID-19 vaccine supply with the world? The White House says it will – but not yet.
International community members say the U.S. and other richer nations should be sharing more its COVID-19 vaccine supply with the rest of the world.
COVID-19 vaccine from AstraZeneca-Oxford slightly less effective than first touted: 76% rather than 79% against disease, updated data shows
More recent clinical trial results show AstraZeneca’s COVID-19 vaccine is slightly less effective in stopping disease than the company first reported.